NCT06044805 (CQ+PQ) is a Phase 4 clinical trial of Chloroquine in Efficacy, sponsored by Dinka Dugassa.

Who is sponsoring NCT06044805?

NCT06044805 is sponsored by Dinka Dugassa.

What drugs are being tested in NCT06044805?

Interventions in NCT06044805: Chloroquine, Primaquine.

What condition does NCT06044805 study?

NCT06044805 studies Efficacy, Malaria, Chloroquine, Vivax Malaria.

Is NCT06044805 still recruiting?

NCT06044805 is currently completed. Last updated 22 September 2023.

Last reviewed 2023-09-22 · How we verify

NCT06044805: CQ+PQ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax

Completed Phase 4 Last updated 22 September 2023

What this trial tests

Phase 4 trial testing Chloroquine in Efficacy in 100 participants. Completed in 15 March 2023.

Timeline

19 December 2022

Primary endpoint
13 March 2023

15 March 2023

Quick facts

Lead sponsor	Dinka Dugassa
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	19 December 2022
Primary completion	13 March 2023
Estimated completion	15 March 2023
Sites	1 location across Ethiopia

Drugs / interventions tested

Chloroquine (CHLOROQUINE) — full drug profile →
Primaquine — full drug profile →

Conditions studied

Efficacy — all drugs for Efficacy →
Malaria — all drugs for Malaria →
Chloroquine — all drugs for Chloroquine →
Vivax Malaria — all drugs for Vivax Malaria →

Sponsor

Dinka Dugassa

Who can join

6 Months and older, any sex, with Efficacy or Malaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this open label clinical trial will be to assess the therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax in Shecha Health Center, South Ethiopia. The main question it aims to answer:- the current therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax in Shecha Health Center, South Ethiopia based on clinical, parasitological and hematological parameter. Participants will be patients aged \>6 months with diagnosis of plasmodium vivax mono-infection and who fulfills the inclusion criteria. This is a single arm open label invivo therapeutic efficacy study of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax. The final result will be compared with World Health Organization recommendation on antimalarial drug therapeutic efficacy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Chloroquine

Trials testing the same drug.

NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06666491 — An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken · Phase 3 · recruiting
NCT04704999 — Southeast Asia Dose Optimization of Tafenoquine · Phase 4 · recruiting
NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn
NCT05980156 — Comparing Chemoprevention Drugs for School-based Malaria Control · Phase 4 · completed

Other recruiting trials for Efficacy

Currently open trials in the same condition.

NCT06976229 — Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase · Phase 1 · recruiting
NCT07000669 — Bilateral Peribulbar Block for Cataract Surgery · recruiting
NCT06642428 — Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast C · NA · recruiting
NCT07323251 — Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Prog · NA · recruiting
NCT06281886 — Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advance · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06044805 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dinka Dugassa
Last refreshed: 22 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06044805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing